Theratechnologies Inc. (TH.TO)
| Previous Close | 2.0000 |
| Open | 1.9500 |
| Bid | 2.0000 x 0 |
| Ask | 2.0100 x 0 |
| Day's Range | 1.9500 - 2.0500 |
| 52 Week Range | 1.2200 - 4.4500 |
| Volume | |
| Avg. Volume | 16,758 |
| Market Cap | 91.96M |
| Beta (5Y Monthly) | 1.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1800 |
| Earnings Date | Sept 24, 2024 - Sept 30, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.43 |
Simply Wall St.Theratechnologies Second Quarter 2024 Earnings: Beats Expectations
Theratechnologies ( TSE:TH ) Second Quarter 2024 Results Key Financial Results Revenue: US$22.0m (up 26% from 2Q 2023...
ZacksDespite Fast-paced Momentum, Theratechnologies (THTX) Is Still a Bargain Stock
Theratechnologies (THTX) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
GlobeNewswireTheratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
Q2 revenue of $22 million represents +25% growth year-over-yearPositive net income of $1 million realized with Adjusted EBITDA1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 million MONTREAL, July 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapie
